Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH (ESRA)
Efficacy and Safety of Riociguat (MK-4836) in Incipient Pulmonary Vascular Disease as an Indicator for Early Pulmonary Arterial Hypertension Double-blind, Randomized, Multicenter, Multinational, Placebo-controlled Phase IIa Study (ESRA)
Sponsor: Heidelberg University
Terminated
Strategic re-prioritization by the IMP supplier. Decision not safety-related.
Listed as NCT05339087, this PHASE2 trial focuses on Other Systemic Involvement of Connective Tissue and Primary Pulmonary Hypertension and remains terminated or withdrawn. Sponsored by Heidelberg University, it has been updated 13 times since 2022, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Aug 2025 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2023 — Jul 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Heidelberg University
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .